Windtree Therapeutics Inkomsten in het verleden
Verleden criteriumcontroles 0/6
Windtree Therapeutics has been growing earnings at an average annual rate of 9.8%, while the Biotechs industry saw earnings growing at 19% annually. Revenues have been declining at an average rate of 99.7% per year.
Belangrijke informatie
9.8%
Groei van de winst
39.9%
Groei van de winst per aandeel
Biotechs Groei van de industrie | 17.0% |
Inkomstengroei | -99.7% |
Rendement op eigen vermogen | -325.8% |
Nettomarge | n/a |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Windtree Therapeutics CEO Craig Fraser - Breaking Down Acute Heart Failure (Video)
Dec 06Windtree Therapeutics: Addressing Underserved And Expensive Acute Conditions
Jul 06Shareholders Will Likely Find Windtree Therapeutics, Inc.'s (NASDAQ:WINT) CEO Compensation Acceptable
Jun 09Should You Take Comfort From Insider Transactions At Windtree Therapeutics, Inc. (NASDAQ:WINT)?
Feb 09Opbrengsten en kosten
Hoe Windtree Therapeutics geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 0 | -11 | 8 | 17 |
31 Mar 24 | 0 | -6 | 9 | 9 |
31 Dec 23 | 0 | -20 | 9 | 8 |
30 Sep 23 | 0 | -25 | 10 | 6 |
30 Jun 23 | 0 | -24 | 10 | 6 |
31 Mar 23 | 0 | -35 | 10 | 7 |
31 Dec 22 | 0 | -39 | 11 | 11 |
30 Sep 22 | 0 | -43 | 12 | 14 |
30 Jun 22 | 0 | -47 | 12 | 17 |
31 Mar 22 | 0 | -67 | 13 | 18 |
31 Dec 21 | 0 | -68 | 14 | 18 |
30 Sep 21 | 0 | -62 | 15 | 29 |
30 Jun 21 | 0 | -63 | 15 | 24 |
31 Mar 21 | 0 | -35 | 15 | 20 |
31 Dec 20 | 0 | -33 | 14 | 15 |
30 Sep 20 | 0 | -32 | 13 | 0 |
30 Jun 20 | 0 | -31 | 13 | 0 |
31 Mar 20 | 0 | -27 | 12 | 0 |
31 Dec 19 | 0 | -27 | 12 | 0 |
30 Sep 19 | 1 | -43 | 13 | 0 |
30 Jun 19 | 1 | -40 | 11 | 0 |
31 Mar 19 | 2 | -37 | 9 | 0 |
31 Dec 18 | 2 | -35 | 7 | 0 |
30 Sep 18 | 2 | -9 | 6 | 0 |
30 Jun 18 | 1 | -13 | 6 | 0 |
31 Mar 18 | 1 | -17 | 7 | 0 |
31 Dec 17 | 1 | -25 | 7 | 0 |
30 Sep 17 | 2 | -34 | 7 | 0 |
30 Jun 17 | 3 | -35 | 7 | 0 |
31 Mar 17 | 2 | -38 | 7 | 0 |
31 Dec 16 | 2 | -39 | 7 | 0 |
30 Sep 16 | 2 | -43 | 8 | 0 |
30 Jun 16 | 1 | -56 | 8 | 0 |
31 Mar 16 | 1 | -57 | 10 | 0 |
31 Dec 15 | 1 | -55 | 11 | 0 |
30 Sep 15 | 2 | -56 | 13 | 0 |
30 Jun 15 | 2 | -45 | 15 | 0 |
31 Mar 15 | 3 | -45 | 16 | 0 |
31 Dec 14 | 3 | -44 | 17 | 0 |
30 Sep 14 | 2 | -45 | 17 | 0 |
30 Jun 14 | 1 | -46 | 17 | 0 |
31 Mar 14 | 0 | -44 | 17 | 0 |
31 Dec 13 | 0 | -45 | 17 | 0 |
Kwaliteitswinsten: WINT is currently unprofitable.
Groeiende winstmarge: WINT is currently unprofitable.
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: WINT is unprofitable, but has reduced losses over the past 5 years at a rate of 9.8% per year.
Versnelling van de groei: Unable to compare WINT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Winst versus industrie: WINT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rendement op eigen vermogen
Hoge ROE: WINT has a negative Return on Equity (-325.82%), as it is currently unprofitable.